Clinical Trials Logo

Zika Virus Infection clinical trials

View clinical trials related to Zika Virus Infection.

Filter by:

NCT ID: NCT06334393 Recruiting - Clinical trials for Zika Virus Infection

Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults

Start date: March 25, 2024
Phase: Phase 1
Study type: Interventional

This phase 1 clinical trial consists of an initial open-label sentinel run-in (n=25) and a randomized, double-blind, dose-finding (n=125) investigating three antigen dose levels (low, medium and high) of VLA1601 and bedside mixing of the low-dose formulation with one of the two additional adjuvants (CpG1018®, 3M-052-AF/AP 60-702). VLA1601 will be administered according to a two-dose regimen (i.e., on Day 1 and Day 29). The primary objective of this trial is to assess the safety and tolerability of the vaccine candidate up to 7 days after each vaccination; and to assess the immune response induced by the vaccine candidate 28 days after the second vaccination. Additionally, safety and immune response of the vaccine candidate will be monitored throughout the trial.

NCT ID: NCT05589012 Not yet recruiting - Clinical trials for Zika Virus Infection

Evaluation of Viral Replication by Tonate Virus (TONV) and Zika Virus (ZIKV), Within an ex Vivo Trophoblast and Placental Model

ZITOPEx
Start date: November 1, 2023
Phase:
Study type: Observational

Prospective, non-interventional study carried out after culturing placental trophoblastic tissue ex vivo and infection with Zika and Tonate

NCT ID: NCT05469802 Withdrawn - Healthy Volunteers Clinical Trials

A Study of Purified Inactivated Zika Virus Vaccine (PIZV) in Healthy Adults

Start date: January 2, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to describe the side effects and immune response of a candidate vaccine that might protect against Zika. The vaccine called PIZV (purified inactivated Zika virus vaccine) is given by injection in two doses that are 28 days apart in healthy adults. Participants will receive PIZV or placebo and will be followed for 7 days after each dose and up to 6 months after dose 2.

NCT ID: NCT05123222 Recruiting - Zika Virus Clinical Trials

Evaluation of Two Zika Viruses for Use in Controlled Human Infection Models (CHIM)

Start date: February 16, 2022
Phase: Phase 1
Study type: Interventional

This study will include 4 cohorts of 14 ZIKV and DENV-naïve female and male subjects, 18 - 40 years of age (total: up to 56 subjects). Within each cohort, 10 subjects will receive ZIKV and 4 subjects will receive a placebo on Study Day 0. Cohorts 1 and 2 (Dose = 10^2 PFU) will be enrolled first and will enroll only women. Cohorts 3 and 4 (Dose = 10^2 PFU) will enroll men.

NCT ID: NCT05041439 Completed - Adherence, Patient Clinical Trials

Adherence to Care for Children With Congenital Zika Virus Infection in Puerto Rico

Start date: July 6, 2021
Phase: N/A
Study type: Interventional

Given the magnitude of the epidemic in Puerto Rico, congenital Zika virus infection may have devastating complications to a significant population of children, also affecting families and society at large. This proposal takes a critical first step to ensuring that children with exposure to congenital Zika virus infection receive the follow-up care they need for optimal clinical outcomes. We anticipate that lessons learned from this study may also positively impact models for adherence to early intervention services in Puerto Rico.

NCT ID: NCT04917861 Active, not recruiting - Zika Virus Clinical Trials

A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas

Start date: June 8, 2021
Phase: Phase 2
Study type: Interventional

This clinical study will evaluate the safety, tolerability, and reactogenicity of 2 dose levels of messenger RNA (mRNA)-1893 Zika vaccine in comparison to a placebo control in healthy participants who are flavivirus-seronegative and in participants who are flavivirus-seropositive.

NCT ID: NCT04697147 Completed - Development, Child Clinical Trials

Zika and Neurodevelopment Among Infants in Grenada

Start date: September 3, 2018
Phase: N/A
Study type: Interventional

Implement a randomized controlled trial, evidence-based, culturally adapted, environmental enrichment intervention for the purpose of enhancing neurocognitive outcomes among Zika Exposed Children.

NCT ID: NCT04478656 Completed - Clinical trials for Zika Virus Infection

Safety and Immunogenicity of BBV121

Zika
Start date: June 3, 2017
Phase: Phase 1
Study type: Interventional

To evaluate the safety, tolerability, and immunogenicity of two-doses of three-sequentially escalating cohort (2.5 µg, 5 µg and 10 µg) of BBV121 (purified inactivated adsorbed Zika virus vaccine) compared with Placebo (Alum). The investigational product is administered intramuscularly on Day 0 and 28 with safety and immunogenicity testing on Day 0, 28 and 56, and Month 6, 9 and 12

NCT ID: NCT04398901 Enrolling by invitation - Child Development Clinical Trials

Neurodevelopmental Outcomes in ZIKV-Exposed Children

Start date: November 23, 2020
Phase:
Study type: Observational

In this study the investigators will follow the neurodevelopmental outcome of children with in utero ZIKV exposure who do not have microcephaly or severe abnormalities consistent with Congenital Zika Syndrome. The ZIKV-exposed children will be compared to non-ZIKV exposed controls. Children will be assessed at age 3 and 4 years using standardized neurodevelopmental assessments. Children will also have neurodevelopmental assessment at age 5 and 7 years along with a brain MRI at age 7 years.

NCT ID: NCT04182685 Enrolling by invitation - Zika Virus Clinical Trials

Evaluation of Medical Conditions Associated With Zika Virus Infection in Managua, Nicaragua

Start date: October 1, 2019
Phase:
Study type: Observational

Zika virus (ZIKV) infection spread throughout the Americas with devastating consequences. Recent limited evidence suggests the potential for neurological effects associated with postnatally acquired ZIKV infection in humans; however, the impact on children is unknown. The researchers will conduct a longitudinal study of approximately 450 Nicaraguan children who were ages 2-12 in 2016 to evaluate the presence and persistence of neurological symptoms associated with ZIKV infection and to test whether ZIKV-infected children are at greater risk for developing neurological outcomes compared to uninfected children.